talkbio – Page 9

Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

3 weeks ago talkbio0Tagged Big Pharma, Chris Shibutani, Corporate, external partnerships, Goldman Sachs, Long-Term Strategy, Myers, squibb

Bristol Myers Squibb; Chris Shibutani; Goldman Sachs; Chief Strategy Officer; long-term strategy; biotech analyst; Big Pharma; external partnerships; corporate strategy

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

3 weeks ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

3 weeks ago talkbio0Tagged Bharat, biotech, GMMA platform, low, Microbicides, middle-income countries, Resistance (Psychotherapeutic), Shigella Infections, Shigella Vaccines, SmithKline Beecham, vaccine licensing

GSK; Bharat Biotech; Shigella vaccine; altSonflex1-2-3; vaccine licensing; Shigellosis; GMMA platform; antimicrobial resistance; low and middle-income countries

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

3 weeks ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

3 weeks ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

FDA Approves UroGen’s Chemo-Turned-Gel Drug ZUSDURI Despite Negative Advisory Vote

3 weeks ago talkbio0Tagged AdComm vote, Approved, chemo-turned-gel drug, Clinical Trials, ENVISION, intermediate-risk, low-grade, mitomycin, muscle-invasive bladder cancer, Negative, NON Mouse, ODAC, Sustained-release Mitomycin C Hydrogel Formulation UGN-102, United States Food and Drug Administration, UroGen, ZUSDURI

UroGen; FDA approval; ZUSDURI; UGN-102; chemo-turned-gel drug; mitomycin gel; low-grade intermediate-risk non–muscle-invasive bladder cancer; negative AdComm vote; ENVISION trial; ODAC